Skip to main content

2023 ASCO Annual Meeting June 2-6, 2023 in Chicago, ILUNC Lineberger members and trainees will present cancer research findings at the 2023 American Society of Clinical Oncology annual meeting in Chicago, June 2-6. ASCO is the world’s largest clinical cancer research meeting, with more than 40,000 attendees expected this year.

The UNC Lineberger presentations include:

Friday, June 2, 2023

Education Session

1:00 – 2:15 PM CDT | E450

Management of Multiple Myeloma in Special Patient Populations: No Patient Left Behind

Merging Molecular and Aging Assessments to Guide Therapy in Older Patients With Myeloma

Shakira Jeanene Grant, MBBS

Saturday, June 3, 2023

Poster Session

8:00 – 11:00 AM CDT | Hall A

Genitourinary Cancer—Prostate, Testicular, and Penile

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.

Jeffrey Lee Jensen, MD, PhD (Poster 115)

Developmental Therapeutics—Immunotherapy

A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.

Yara Abdou, MD (Poster 506b)

1:15 – 4:15 PM CDT | Hall A

Health Services Research and Quality Improvement

Patient-level interventions to increase guideline concordant treatment among Black breast cancer patients: Can they close the racial gap in survival after diagnosis?

Juan Yanguela, MS (Poster 41)

Case-Based Panel Session

3:00 – 4:00 PM CDT | S102

Geriatric Oncology | Hematologic Malignancies

Shared Decision-Making for Older Adults With Cancer Using Available Treatment Tools

Chair: Daniel Richardson, MD, MSc

Sunday, June 4, 2023

Poster Session

8:00 – 11:00 AM CDT | Hall A

Breast Cancer

Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829) 

Joannie M. Ivory, MD, MSPH (Poster 276)

Breast Cancer—Metastatic

Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.

Paola Zagami, MD (Poster 330)

Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.

Colette Shen, MD, PhD (Poster 343a)

Monday, June 5, 2023

Education Session

8:00 – 9:15 AM CDT | S404

Structural Sexism and Cancer Care: The Effects on the Patient and Oncologist

Breaking the Glass Ceiling: Gender Equity in the Workplace

Elizabeth Gleeson, MD, MPH

Poster Session

1:15 – 4:15 PM CDT | Hall A

Head and Neck Cancer

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC. 

Colette Shen MD, PhD (Poster 30)

Care Delivery and Regulatory Policy

Comparison of publications between cancer sites in high impact factor journals.

Nikita Sinha, MD (Poster 182)